Guo Xu, Piao Haozhe, Xue Yixue, Liu Yunhui, Zhao Hongyu
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
J Int Med Res. 2020 Sep;48(9):300060520954764. doi: 10.1177/0300060520954764.
To explore the potential of the transcription factor LMX1B and downstream gankyrin as prognostic biomarkers of glioma.
The expression levels of gankyrin and LMX1B were detected in 52 normal brain specimens and 339 glioma specimens. Correlations of gankyrin and LMX1B expression levels with pathological stages and clinical characteristics were statistically analyzed. Furthermore, the binding of LMX1B to the gankyrin promoter was evaluated using ALGGEN PROMO.
Levels of LMX1B and gankyrin were significantly increased in tumor tissue, and were significantly associated with advanced glioma grade and poor survival. Compared with gankyrin- and LMX1B-negative glioma, the mean survival of patients with higher gankyrin and LMX1B expression was significantly reduced, from 83.46 to 18.87 months and from 63.79 to 18.29 months, respectively. Furthermore, LMX1B had a moderate positive correlation with gankyrin expression (Pearson's = 0.650), and it was also found to act as a transcription factor with NF-κB and E47 on the gankyrin promoter.
Increased expression of LMX1B and gankyrin has independent prognostic value in glioma patients. The transcription factor LMX1B may have an upstream role in the mechanism of action.
探讨转录因子LMX1B及其下游的泛素特异性蛋白酶8（gankyrin）作为胶质瘤预后生物标志物的潜力。
检测52例正常脑标本和339例胶质瘤标本中gankyrin和LMX1B的表达水平。对gankyrin和LMX1B表达水平与病理分期及临床特征的相关性进行统计学分析。此外，使用ALGGEN PROMO评估LMX1B与gankyrin启动子的结合情况。
肿瘤组织中LMX1B和gankyrin水平显著升高，且与高级别胶质瘤及较差的生存率显著相关。与gankyrin和LMX1B阴性的胶质瘤相比，gankyrin和LMX1B表达较高的患者平均生存期显著缩短，分别从83.46个月降至18.87个月，从63.79个月降至18.29个月。此外，LMX1B与gankyrin表达呈中度正相关（Pearson's = 0.650），并且还发现它在gankyrin启动子上与核因子κB（NF-κB）和E47共同作为转录因子发挥作用。
LMX1B和gankyrin表达增加在胶质瘤患者中具有独立的预后价值。转录因子LMX1B可能在作用机制中起上游作用。
